Skip to main content
. 2019 Jan 10;104(7):1407–1416. doi: 10.3324/haematol.2018.204487

Figure 2.

Figure 2.

Impact of ERGdel on survival within acute lymphoblastic leukemia (DUX4r-ALL). Five-year event-free survival (EFS) (A, C, E) and overall survival (OS) (B, D, F) of DUX4r-ALL patients stratified according to the presence of ERGdel as defined by single nucleotide polymorphism array (A and B), genomic polymerase chain reaction (C and D), and amplicon sequencing (AmpliSeq) (E and F). n: number.